CN111467327A

CN111467327A - Application of zingiberone A in preparation of colitis prevention and treatment medicines

Info

Publication number: CN111467327A
Application number: CN202010345438.9A
Authority: CN
Inventors: 梁健; 肖红钰
Original assignee: Guangzhou University Of Chinese Medicine Guangzhou Institute Of Chinese Medicine
Current assignee: Guangzhou University Of Chinese Medicine Guangzhou Institute Of Chinese Medicine; Guangzhou University of Chinese Medicine
Priority date: 2020-04-27
Filing date: 2020-04-27
Publication date: 2020-07-31
Anticipated expiration: 2040-04-27
Also published as: CN111467327B

Abstract

The invention discloses an application of zingiberone A in preparing a colitis prevention and treatment drug. The research of the invention shows that the zingiberone A can obviously improve clinical symptoms such as loose stool and bloody stool caused by the colitis, effectively reduce colonic atrophy, reduce colonic thickness, enhance the barrier function of intestinal tracts and inhibit colonic mucosa edema, and has no obvious side effect, so the zingiberone A has obvious effect of preventing and treating the colitis and can be applied to the prevention and treatment aspect of the colitis. The invention not only provides a new application of the zingiberone A, but also provides a new treatment medicament and a new treatment way for treating the colitis.

Description

Application of zingiberone A in preparation of colitis prevention and treatment medicines

Technical Field

The invention belongs to the technical field of biological medicines. More particularly, relates to the application of zingiberone A in preventing and treating colitis.

Background

Colitis (colitis) is one of the clinical multiple intestinal diseases, and is mainly characterized by diarrhea, abdominal pain, mucous stool, bloody purulent stool, tenesmus and even constipation in clinic, and the stool can not be dredged within a few days; it is often accompanied by emaciation, hypodynamia, etc., and is frequently recurrent. Among them, the incidence rate of Ulcerative Colitis (UC) is gradually increasing and the disease course is long, and the death rate of Colorectal cancer (CRC) induced by it is more and more important than that of liver cancer and stomach cancer at present.

At present, the main medicaments for treating colitis are: glucocorticoid, 5-amino salicylic acid, immunosuppressant, etc. However, the therapeutic effects of these drugs have certain limitations. Therefore, the search and development of more ideal drugs or treatment strategies for preventing and treating colitis are urgent.

Disclosure of Invention

The invention aims to overcome the defects of the existing colitis treatment technology, provides the application of the zingiberone A in preparing the medicaments for preventing and treating the colitis, and provides a new medicament choice for preventing and treating the colitis. The medicine has good curative effect on colitis, can remarkably improve clinical symptoms such as loose stool and bloody stool caused by colitis, effectively enhance intestinal barrier function, reduce colonic atrophy, inhibit colonic mucosa edema and further protect colon.

The invention aims to provide application of zingiberone A in preparation of a colitis prevention and treatment drug.

The above purpose of the invention is realized by the following technical scheme:

the research result of the invention shows that the zingiberone A can obviously improve clinical symptoms such as loose stool and bloody stool caused by colitis, effectively reduce colonic atrophy, reduce colonic thickness, enhance intestinal barrier function and inhibit colonic mucosal edema, and has no obvious side effect, so the zingiberone A has obvious effect of preventing and treating colitis. Therefore, the following applications should be within the scope of the present invention:

application of zingiberone A in preparing medicine for preventing and treating colitis is provided.

In addition, specifically, the prevention and treatment of colitis refers to reduction of colonic atrophy, reduction of colonic thickness, enhancement of intestinal barrier function and/or inhibition of colonic mucosal edema.

Preferably, the colitis is ulcerative colitis.

The invention also provides a medicament containing the zingiberone A for preventing and treating the colitis, which is also within the protection scope of the invention. Preferably, the colitis is ulcerative colitis.

In addition, the medicine can also comprise medically acceptable auxiliary materials or carriers, and can be prepared into different formulations or selectively compounded with other medicines.

The invention has the following beneficial effects:

the research of the invention shows that the zingiberone A can obviously improve clinical symptoms such as loose stool, bloody stool and the like caused by the colitis, effectively reduce colonic atrophy, reduce colonic thickness, enhance intestinal barrier function and inhibit colonic mucosa edema, has no obvious side effect and shows obvious prevention and treatment effect on the colitis, so the zingiberone A can be applied to the prevention and treatment aspect of the colitis.

The invention not only provides a new application of the zingiberone A, but also provides a new treatment medicament and a new treatment way for treating the colitis.

Drawings

Figure 1 shows the therapeutic effect of zingiberone a on ulcerative colitis models,

wherein A is the stool dilution score, B is the bloody stool score, C is the colon length, and D is the colon thickness;

FIG. 2 is a graph of the effect of zingiberenone A on colon histopathology in a model of ulcerative colitis;

figure 3 is a graph of zingiberenone a scoring for ulcerative colitis model colon histopathological lesions.

Detailed Description

The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.

Unless otherwise indicated, reagents and materials used in the following examples are commercially available.

Example 1 influence of zingiberenone A on the clinical symptoms and colon Length and thickness of the ulcerative colitis model

1. Experimental animals:

the method is characterized in that the SPF level male BA L B/c mice (6-8 weeks old, 18-22g) are purchased from Guangzhou Chinese medicine university laboratory animal center, the license number is SCXK (Guangdong) 2013-.

2. The experimental method comprises the following steps:

male BA L B/C mice (6-8 weeks old, 18-22g) were acclimatized and housed for 7 days, and then the animals were randomly divided into Normal control group (Normal group), DSS model group, zingenone A low dose group (10mg/kg/day), zingenone A high dose group (40mg/kg/day), Normal control group free to drink distilled water daily, DSS model group and zingenone A administration group free to drink 4% DSS daily, Normal control group and DSS model group animals were fed with distilled water daily in equal amounts, DOPS administration group was administered once daily according to animal body weight, molding was continued for 7 days until the end of the experiment, and the condition of animal state, body weight, feeding, water intake, animal bloody stool and stool blood were recorded daily.

After the experiment, the colon tissue is planed and spread on a cold tray, and the feces in the colon tissue is gently removed by a cotton swab to avoid injuring the colon mucous membrane tissue. The length and thickness of the colon are measured.

3. The experimental results are as follows:

as shown in fig. 1, clinical symptoms of loose stool and bloody stool in animals with Ulcerative Colitis (UC) model were significantly improved after administration of zingiberone a (fig. 1A-B). Further analysis of colon length and colon thickness revealed that in the DSS model group, the colon length was significantly decreased and the colon thickness was significantly increased in comparison to the normal control group (fig. 1C-D); however, compared to the model group, the UC mice had a significantly increased colon length and significantly less colon thickness after treatment with zingiberenone a (fig. 1C-D), which demonstrates that zingiberenone a is effective in alleviating the development of DSS-induced ulcerative colitis.

Example 2 Effect of zingenone A on Colon histopathology in animal models of ulcerative colitis

The colon tissue planed after the experiment of example 1 is taken for the histopathological examination of the colon: colon tissue was fixed in 4% paraformaldehyde fixing solution. After 24h of immersion, the colon tissue was dehydrated and embedded into a wax block. The thickness of the section was 4 μm, and the section was placed in an automatic staining apparatus and subjected to HE staining. After HE dyeing is finished, sealing the piece by using neutral resin. The sections were examined under an optical microscope for tissue morphology and inflammatory infiltration. The results are shown in FIG. 2.

As can be seen from FIG. 2, the DSS model group animals have obviously changed colon tissue structure morphology, a large amount of inflammatory cell infiltration, severe goblet cell necrosis and deletion, obvious goblet cell swelling, colon mucosa exfoliation, incomplete intercellular spaces, irregular glandular structures and severely damaged colon mucosa barriers; after the treatment of the zingiberenone A, the colon tissue structure form of the UC mouse is obviously improved, inflammatory cell infiltration is obviously reduced, and the intestinal mucosa barrier is complete. The DOPS is shown to be capable of enhancing the barrier function of the intestinal mucosa, inhibiting the edema of the colon mucosa, reducing the intestinal inflammation and inhibiting the occurrence and development of the ulcerative colitis.

The above-described embodiments are illustrative of the present invention, but any other modifications which do not depart from the spirit and principle of the invention are intended to be included within the scope of the invention.

Claims

1. Application of zingiberone A in preparing medicine for preventing and treating colitis is provided.

2. The use of claim 1, wherein the prevention and treatment of colitis is reduction of colonic atrophy, reduction of colonic thickness, enhancement of intestinal barrier function and/or inhibition of colonic mucosal edema.

3. Use according to claim 1 or 2, wherein the colitis is ulcerative colitis.

4. A medicine for preventing and treating colitis is characterized by containing zingiberenone A.

5. The medicament of claim 4, wherein the colitis is ulcerative colitis.

6. The medicament of claim 4, further comprising a medically acceptable adjuvant or carrier.